Novavax, Inc. (NVAX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous close | 79.18 |
| Open | 81.23 |
| Bid | 72.91 x 800 |
| Ask | 74.25 x 1000 |
| Day's range | 71.71 - 81.58 |
| 52-week range | 66.38 - 331.68 |
| Volume | |
| Avg. volume | 6,281,763 |
| Market cap | 5.513B |
| Beta (5Y monthly) | 1.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -14.95 |
| Earnings date | 28 Feb 2022 - 04 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 250.00 |
- Editor's pickYahoo Finance Video
Trump’s Operation Warp Speed was 'very helpful' for vaccine development: Gregory Zuckerman
‘A Shot to Save the World’ author, Gregory Zuckerman joins 'Influencers with Andy Serwer' to discuss the Trump Administration's role in developing the COVID-19 vaccines.
- Motley Fool
Why Novavax Stock Is Sinking Again This Week
Investors appear to be concerned about Pfizer's and BioNTech's head start in developing an omicron-specific vaccine.
- Motley Fool
1 Top Biotech Stock Ready for a Bull Run
The road to FDA approval can be long, and in the case of COVID-19 vaccines, there is no time for delays and no room for error. One company that has come to understand this very well is Novavax (NASDAQ: NVAX). Since 2020, the company has been developing a vaccine to help prevent and fight the impact of COVID-19.
© 2022 Yahoo. All rights reserved.
